Glenmark Pharmaceuticals Limited's total assets for Q2 2026 were ₹190.02B, an increase of Infinity% from the previous quarter. IN:GLENMARK total liabilities were ₹94.20B for the fiscal quarter, a -206.46% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.